Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher (TMO) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
TMO to Report Q2 Earnings: Analytical Instruments Segment in Focus
Thermo Fisher eyes second-quarter 2025 growth with new tech launches in Analytical Instruments and Life-Science Solutions segments.
Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
TMO's growth via acquisitions and product launches is strong, but macro pressures and FX headwinds cloud the outlook.
Thermo Fisher Scientific: Recovery In Sight, Attractively Valued
Thermo Fisher has good growth prospects ahead. Core pharma, biotech, and bioproduction businesses are driving growth, with US manufacturing investments and the Solventum acquisition strengthening future prospects. Margins remain under near-term pressure from tariffs and strategic investments, but productivity gains and pricing actions provide a cushion and set up for future expansion.
Report: Biotech Research Firm Thermo Fisher Considers Selling Diagnostics Business
Biotechnology research firm Thermo Fisher Scientific is reportedly looking to sell part of its diagnostics business amid industrywide concerns about federal cutbacks in spending on research.
Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition
TMO grapples with macro pressures, rising expenses and fierce competition, but bets on acquisitions to fuel recovery.
TMO Launches Next-Generation Mass Spectrometers: Stock to Gain?
Thermo Fisher debuts two advanced MSs, Orbitrap Astral Zoom and Orbitrap Excedion Pro, to accelerate precision medicine and drug discovery breakthroughs.
Thermo Fisher: With A 30% Price Drop, Trump Legislation, And High Capex, Is It Undervalued?
The neutral DCF model implemented in this article suggests that Thermo Fisher is undervalued by 29.24%. Thermo Fisher has invested, on average, 16.51% of its revenues in capex between 2019 and 2024. Due to the significant investment in capex, Thermo Fisher's revenues have increased at a 12.95% CAGR between 2019 and 2024.
Thermo Fisher Is Strengthening Its Long-Term Advantage
Thermo Fisher's 2025 headwinds from tariffs and US research funding cuts are real but temporary, not reflective of structural weakness in its fundamentals. The company is mitigating trade impacts by investing $2B in US manufacturing, leveraging diversification and innovation, and expects headwinds to peak this year. Biopharma growth, strategic acquisitions, and rapid product innovation position TMO for long-term outperformance versus less diversified peers.
Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain?
TMO unveils spectral-enabled Attune Xenith Flow Cytometer to streamline workflows and boost research accuracy.
TMO Stock Set to Gain From the Launch of New Narcotic Analyzers
Thermo Fisher launches new TruNarc analyzers to help law enforcement quickly detect 1,200+ substances, boosting field safety and drug interdiction efforts.
